SOURCE: Geonostics, Inc.

Geonostics, Inc.

November 16, 2010 12:02 ET

Geonostics Acquires FlexSite's Consumer Diabetes Tests

LINCOLNSHIRE, IL--(Marketwire - November 16, 2010) - Geonostics, Inc, the leader in micro-sample blood collection, processing, and transport services, announced today the acquisition of FlexSite Diagnostics of Palm City, FL. Possessing the only FDA-cleared home tests for Hemoglobin A1c (A1c) and kidney screening, FlexSite has been the industry pioneer in providing patient direct diabetes testing services to consumers, university studies, managed care, diabetic supply companies, and drug manufacturers. FlexSite's founder and Chief Executive Officer, Robert Ray, PhD, will join Geonostics as Scientific Advisor to focus on several research and development projects, including next generation intellectual property for the company.

A1c testing has long been the standard by which physicians monitor the effectiveness of diabetes therapy, and has recently been endorsed by the American Diabetes Association (ADA) as an accurate aid in the diagnosis of the disease. With diabetes reaching epidemic proportions within the US, testing for the disease, and subsequent monitoring of its progression, has become more important than ever. The A1c test measures total glycated hemoglobin, which accurately determines a patient's average blood glucose (blood sugar) level over the previous 60 to 90 days.

"In October, the Centers for Disease Control announced that estimates show as much as one third of the U.S. population will have diabetes by 2050," said David Fleisner, Geonostics' Chief Executive Officer. "With the ADA now recognizing the value of A1c testing for its ability to detect diabetes in its early stages, we have an opportunity to make a significant and positive impact on the current trend and ultimately improving patient's lives."

About Geonostics
Geonostics is the leader in micro-sample blood diagnostics, providing specialized clinical laboratory services throughout the United States as well as internationally. The company's focus is on providing key clinical laboratory values to assist in the prevention, prediction, management, and treatment of chronic diseases, including diabetes, cardiovascular, asthma, allergies, and chronic obstructive pulmonary disease (COPD).

For additional information about Geonostics and FlexSite visit www.geonostics.com and www.flexsite.com.

Contact Information